Clinical trial
Chemotherapy With Pemetrexed in Combination With Platinum for Advanced Non-Small…
NCT00402051 · Eli Lilly and Company, Industry · Completed
Key facts
| NCT number | NCT00402051 |
|---|---|
| Title | Chemotherapy With Pemetrexed in Combination With Platinum for Advanced Non-Small Cell Lung Cancer (NSCLC) |
| Official title | A Randomized Phase 2 Study of Pemetrexed in Combination With Cisplatin or Carboplatin in the First Line Therapy of Advanced NSCLC |
| Lead sponsor | Eli Lilly and Company, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Non-Small-Cell Lung Cancer |
| Intervention type | Drug |
| Interventions | Pemetrexed, Cisplatin, Carboplatin |
| Enrollment | 133 |
| Start date | Nov 1, 2006 |
| Primary completion | Dec 1, 2008 |
| Completion | May 1, 2009 |
| First posted | Nov 22, 2006 |
| Last update posted | Feb 17, 2010 |
| Countries | Germany |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: